Netflix Shares Look Fantastic
Netflix (NFLX) Michael Wall, President of Retire Well, LLC. " There is a lot of growth in other markets and other countries that they still have yet to tap.
in it to win it
"We rate XOMA CORP (XOMA) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally disappointing historical performance in the stock itself."
GOOD DD READ
Ironwood Pharmaceuticals Whittled Down
Tolerability data for Synergy Pharma’s chronic idiopathic constipation treatment top Ironwood’s Linzess.
Synergy Pharmaceuticals ( SGYP ) reported positive data for plecanatide in a Phase 3 study of 1,346 patients with chronic idiopathic constipation (CIC). Synergy Pharma’s results are favorably to the results from Ironwood’s two CIC trials. Also importantly, tolerability data to favor plecanatide over Linzess
By: Bret Kenell
Fitbit has unbelievable growth and is already profitable, which is a big deal for a newly public company.
The valuation is attractive, too. GoPro (GPRO) and Under Armour (UA) both have slower growth rates, yet have higher valuations that Fitbit. If Fitbit traded with the same valuation as Under Armour, it would be $72.
Fitbit is bringing its fitness wearables to India
Kunal Sehgal & Maria Thomas
The world’s largest wearables company is coming to India.
Founded in 2007, Fitbit commands 85% of the global health wearables market Demand for wearables is surging around the world, with shipments expected to jump 173% this year, according to a report by research firm IDC.San Francisco-headquartered Fitbit will partner with e-commerce firm Amazon to offer four types of wearable bands to help Indian consumers track their fitness
do the DD